think amgen offer to buy cytk is not far away. think blum will hint at it on wed. but actual offer will come when cytk does its secondary offering maybe a week or two after om results are released. with astellas not getting tiras that tells me that amgen told cytk that tiras must be thrown in in purchase deal. tiras is a crapshoot. any als drug has a very slim chance of fda approval. tiras appears to have a shot at approval but the odds are long. think amgen offer to buy cytk will coincide with secondary offering.
Hope it will be interesting to discuss the course of CYTK. They should touch on the reasoning behind the reverse split. This could be the start of upward momentum for CYTK. All aboard before you get left behind.